Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new stem cell combo therapy called OSCA delivered substantial, sustained pain relief and early signs of tissue repair in patients with moderate knee osteoarthritis — a group with very few treatment options. Phase 2a trial results presented at ACR Convergence showed significant improvements in pain, function, and inflammation biomarkers compared to placebo, with no serious adverse events.
A single injection that may do more than just relieve pain. For patients with moderate knee osteoarthritis — too symptomatic for conservative care but too early for joint replacement — treatment options have long been frustratingly limited. A new combination therapy called OSCA (osiramestrocel + acellular cartilage matrix) may be changing that. Phase 2a data presented at ACR Convergence 2026 showed that a single intra-articular injection delivered meaningful, sustained pain relief and early structural improvements over six months.
The multicenter, randomized, placebo-controlled trial enrolled 113 patients across two active dose groups and placebo. Both doses significantly outperformed placebo on pain (VAS), function (WOMAC, KOOS, IKDC), and responder rates — with the mid-dose showing particularly strong MRI-based cartilage repair signals. Inflammatory biomarkers including TNF-α, IL-1β, and cartilage degradation markers also improved significantly in the high-dose group. Adverse events were mild, and no serious treatment-related events occurred.
By the Numbers:
Why it matters: OSCA combines stem cell treatment with early signals of structural cartilage repair — potentially offering a disease-modifying option where none currently exists. Researchers say the data provide a strong foundation for phase 2b/3 trials.
